{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:46:48Z","timestamp":1790786808309,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Aichi Cancer Center Joint Research Project on Priority Areas","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Takara Bio, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ono Pharmaceutical Foundation for Oncology, Immunology, and Neurology","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Chugai Foundation for Innovative Drug Discovery Science","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K27470"],"award-info":[{"award-number":["23K27470"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K22072"],"award-info":[{"award-number":["24K22072"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016980","name":"Otsuka Toshimi Scholarship Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100016980","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JST FOREST Program","award":["JPMJFR2060"],"award-info":[{"award-number":["JPMJFR2060"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ama221303"],"award-info":[{"award-number":["JP22ama221303"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22bm0704066"],"award-info":[{"award-number":["JP22bm0704066"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ym0126072"],"award-info":[{"award-number":["JP22ym0126072"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22zf0127009"],"award-info":[{"award-number":["JP22zf0127009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ama221331"],"award-info":[{"award-number":["JP24ama221331"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24bm1123051"],"award-info":[{"award-number":["JP24bm1123051"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25bk0104186"],"award-info":[{"award-number":["JP25bk0104186"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,28]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>While chimeric antigen receptor (CAR)-T cell therapy exhibits a robust therapeutic efficacy against B-cell malignancies and multiple myeloma, its efficacy and safety have not been established for acute myeloid leukemia (AML) and solid tumors due to the paucity of established target antigens. Some AML and solid tumor cells express tumor necrosis factor (TNF), which is initially expressed on the cell surface prior to shedding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, we obtained monoclonal antibodies against the N-terminal fragment of TNF (TNF-NTF) that remains on the cell surface after shedding. We then generated CAR-T cells to target TNF-NTF using the antibody sequence. To enhance the therapeutic efficacy of TNF-NTF CAR-T cells, we further engineered the previously developed chimeric cytokine receptor consisting of GP130, IL6R, and constitutively active IL7R with the M452L mutation (G6\/7R).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TNF-NTF CAR-T cells efficiently lysed TNF-expressing leukemia cells <jats:italic>in vitro<\/jats:italic>, while showing limited antitumor efficacy <jats:italic>in vivo<\/jats:italic> due to poor expansion and persistence. Activated T cells upregulate TNF, which was recognized by TNF-NTF CAR-T cells and led to fratricide. Genetic knockout (KO) of <jats:italic>TNF<\/jats:italic> significantly enhanced the viability and proliferation of TNF-NTF CAR-T cells, while slightly reducing their cytotoxic activity. In addition, ectopic expression of G6\/7R improved the effector function of TNF-NTF CAR-T cells through constitutive activation of janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling. The G6\/7R-expressing <jats:italic>TNF<\/jats:italic>-KO TNF-NTF CAR-T cells exhibited superior persistence and durable antileukemic efficacy <jats:italic>in vivo<\/jats:italic> compared with parental CAR-T cells. We also confirmed that TNF-NTF CAR-T cells can target primary AML cells, including a leukemia-initiating population with colony-forming capacity. Unlike CD33, targeting TNF-NTF did not show cytotoxicity against normal hematopoietic stem\/progenitor cells. Finally, we demonstrated the curative efficacy of G6\/7R <jats:italic>TNF<\/jats:italic>-KO TNF-NTF CAR-T cells against TNF-expressing ovarian tumor cells <jats:italic>in vivo<\/jats:italic>.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our studies highlight TNF-NTF as a promising cell surface target for CAR-T cell therapy that can be applied to AML as well as solid tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-011067","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T03:50:21Z","timestamp":1752465021000},"page":"e011067","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumors"],"prefix":"10.1136","volume":"13","author":[{"given":"Takahiro","family":"Nakashima","sequence":"first","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"},{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Ouchida","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haosong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"},{"name":"Division of Cellular Oncology, Department of Cancer Diagnostics and Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Kasuya","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"},{"name":"Division of Cellular Oncology, Department of Cancer Diagnostics and Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"},{"name":"Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-6730","authenticated-orcid":false,"given":"Yuki","family":"Kagoya","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"},{"name":"Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"2025100306321777000_13.7.e011067.1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25162"},{"key":"2025100306321777000_13.7.e011067.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.813"},{"key":"2025100306321777000_13.7.e011067.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3714"},{"key":"2025100306321777000_13.7.e011067.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100306321777000_13.7.e011067.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100306321777000_13.7.e011067.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100306321777000_13.7.e011067.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.004"},{"key":"2025100306321777000_13.7.e011067.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100306321777000_13.7.e011067.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056"},{"key":"2025100306321777000_13.7.e011067.10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"2025100306321777000_13.7.e011067.11","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164"},{"key":"2025100306321777000_13.7.e011067.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2"},{"key":"2025100306321777000_13.7.e011067.13","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"2025100306321777000_13.7.e011067.14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"2025100306321777000_13.7.e011067.15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"2025100306321777000_13.7.e011067.16","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.2147\/OTT.S205678","article-title":"IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell","volume":"12","author":"Sun","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2025100306321777000_13.7.e011067.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68101"},{"key":"2025100306321777000_13.7.e011067.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2019.05.019"},{"key":"2025100306321777000_13.7.e011067.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4336"},{"key":"2025100306321777000_13.7.e011067.20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402356"},{"key":"2025100306321777000_13.7.e011067.21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.044347"},{"key":"2025100306321777000_13.7.e011067.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403193200"},{"key":"2025100306321777000_13.7.e011067.23","doi-asserted-by":"publisher","DOI":"10.1267\/ahc.06001"},{"key":"2025100306321777000_13.7.e011067.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012714"},{"key":"2025100306321777000_13.7.e011067.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101526","article-title":"Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells","volume":"5","author":"Yoshikawa","year":"2024","journal-title":"Cell Rep Med"},{"key":"2025100306321777000_13.7.e011067.26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/nar\/gkad1076","article-title":"Epigenetic profiles guide improved CRISPR\/Cas9-mediated gene knockout in human T cells","volume":"52","author":"Ito","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2025100306321777000_13.7.e011067.27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130990"},{"key":"2025100306321777000_13.7.e011067.28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0145-2126(02)00081-4","article-title":"Megakaryoblastic leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with myeloid\/NK precursor phenotype","volume":"27","author":"Matsuo","year":"2003","journal-title":"Leuk Res"},{"key":"2025100306321777000_13.7.e011067.29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"2025100306321777000_13.7.e011067.30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003837","article-title":"Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers","volume":"11","author":"Ba","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100306321777000_13.7.e011067.31","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90106-L"},{"key":"2025100306321777000_13.7.e011067.32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945"},{"key":"2025100306321777000_13.7.e011067.33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2415"},{"key":"2025100306321777000_13.7.e011067.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.04.001"},{"key":"2025100306321777000_13.7.e011067.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-104042"},{"key":"2025100306321777000_13.7.e011067.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2301"},{"key":"2025100306321777000_13.7.e011067.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.03.018"},{"key":"2025100306321777000_13.7.e011067.38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118094"},{"key":"2025100306321777000_13.7.e011067.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01703-0"},{"key":"2025100306321777000_13.7.e011067.40","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0155"},{"key":"2025100306321777000_13.7.e011067.41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307"},{"key":"2025100306321777000_13.7.e011067.42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"2025100306321777000_13.7.e011067.43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature New Biol"},{"key":"2025100306321777000_13.7.e011067.44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32567"},{"key":"2025100306321777000_13.7.e011067.45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature New Biol"},{"key":"2025100306321777000_13.7.e011067.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02019"},{"key":"2025100306321777000_13.7.e011067.47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39065"},{"key":"2025100306321777000_13.7.e011067.48","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209945"},{"key":"2025100306321777000_13.7.e011067.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.09.002"},{"key":"2025100306321777000_13.7.e011067.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203195"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:32:23Z","timestamp":1759498343000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,13]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2024-011067"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011067","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}